Testing two chemo combos for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 trial compares two chemotherapy combinations to see which works better for advanced triple-negative breast cancer. You would be asked to join one treatment arm based on study assignment and be followed for response and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and age 18 to 70
- Your breast cancer is confirmed to be triple-negative
- You have not had more than one prior treatment for advanced or metastatic breast cancer
- You have at least one tumor spot that can be measured, and your health is good enough to do daily activities (ECOG 0–1)
- Your blood counts, kidney function, and liver tests meet minimum levels
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
This trial tests a new drug called SKB264 against standard chemotherapy options for people with advanced triple-negative breast cancer who have not yet received chemotherapy for their advanced disease. The goal is to see if SKB264 works better than the usual treatments.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This trial tests a new combination of three drugs (camrelizumab, apatinib, and eribulin) against the standard chemotherapy chosen by your doctor. It's for people with advanced triple-negative breast cancer that has gotten worse after previous treatments.
This trial looks at different ways to use the chemotherapy drug capecitabine for people with triple-negative breast cancer who still have cancer cells after initial treatment and surgery. It aims to find the best approach to improve outcomes.
This trial tests whether a special PET scan can help guide the best combination of chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. It aims to personalize treatment and improve outcomes.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.